Eisai Sues Mylan Over Aciphex ANDA

Law360, New York (January 30, 2004, 12:00 AM EST) -- Japanese pharmaceutical company Eisai has filed a lawsuit in the U.S. District Court for the Southern District of New York against generics maker Mylan Laboratories over its abbreviated new drug application for a generic version of ulcer medicine Aciphex.

Eisai said its rabeprazole composition of matter patent is valid until its expiration date of May 8, 2013.

In November, Eisai sued Indian generics maker Dr. Reddy's and Israeli generics marker Teva in the same court for patent infringement over their ANDA application for an Aciphex equivalent....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.